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Abstract
Background: Sensitivity analyses are an important tool for understanding the extent to which the results of
randomised trials depend upon the assumptions of the analysis. There is currently no guidance governing the choice
of sensitivity analyses.
Discussion: We provide a principled approach to choosing sensitivity analyses through the consideration of the
following questions: 1) Does the proposed sensitivity analysis address the same question as the primary analysis? 2) Is
it possible for the proposed sensitivity analysis to return a different result to the primary analysis? 3) If the results do
differ, is there any uncertainty as to which will be believed? Answering all of these questions in the affirmative will
help researchers to identify relevant sensitivity analyses. Treating analyses as sensitivity analyses when one or more of
the answers are negative can be misleading and confuse the interpretation of studies. The value of these questions is
illustrated with several examples.
Summary: By removing unreasonable analyses that might have been performed, these questions will lead to
relevant sensitivity analyses, which help to assess the robustness of trial results.
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Background
In randomised trials researchers are required to specify
analyses before seeing the outcome data, to select one
of these as the primary analysis, (ideally) to make this
plan public, and to adhere to the specified analyses on
receipt of the outcome data. There are two reasons for this
approach. First, it prevents researchers from cherry pick-
ing their favoured analyses after seeing the data. Second,
choosing the method for the primary analysis based on
trial data has been shown to lead to unreliable results in
several settings [1-4].
Pre-specified analyses make assumptions that may be
strong, unverifiable, or not supported by the data. ‘Sensi-
tivity analysis’ aims to investigate whether the results of
important analyses are sensitive or robust to violations
of the assumptions by performing analyses addressing a
specific clinical question under contrasting assumptions.
Despite articles advocating sensitivity analysis [5], there
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are currently no principles governing how relevant sen-
sitivity analyses should be chosen. The following three
questions should be considered to determine whether a
sensitivity analysis is worthwhile:
1. Does the proposed sensitivity analysis address the
same question as the primary analysis?
2. Is it possible for the proposed sensitivity analysis to
arrive at a different conclusion to the primary
analysis?
3. If the proposed sensitivity analysis leads to a different
conclusion to the primary analysis, is there a genuine
degree of uncertainty as to which will be believed?
To qualify as a sensitivity analysis, the answer to all of
the above questions should be yes. Analyses that address
different questions to the primary analysis may be impor-
tant, but should be classified as secondary, not sensitivity
analyses; considering them as sensitivity analysesmay lead
to false anxiety about the robustness of results. Analyses
that will always lead to the same conclusion as the primary
analysis are dangerous, as they falsely reassure us about
the robustness of results. If there is no uncertainty as to
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which analysis is more believable, the analysis that would
not be believed should be dropped.
Below, we expand on the reasons for asking each ques-
tion, and demonstrate their usage with some real exam-
ples. Because we are advocating the use of these questions
at the stage of writing the statistical analysis plan, we do
not consider the results of our examples, but whether the
sensitivity analysis described is worthwhile. Figure 1 is
provided as a quick reference tool.
Discussion
Does the proposed sensitivity analysis address the same
question as the primary analysis?
It would seem very strange to consider how sensitive an
answer is to the question being asked. We should be look-
ing at how sensitive an answer is to asking the question in
a different way. If two seemingly similar analyses address
different questions, the proposed sensitivity analysis is
correctly regarded as a secondary analysis (note that we
use ‘secondary’ to refer to a secondary analysis rather than
the analysis of a secondary outcome).
Example
The Multicentre Aneurysm Screening Study group ran-
domised 67,800 men to receive an invitation to an abdom-
inal ultrasound scan or not [6]. Of those invited to receive
an abdominal scan, 20% did not accept. The primary anal-
ysis was by intention to treat, thus estimating the effect
of being randomised to abdominal ultrasound. Another
analysis investigated the complier average causal effect,
which considers what the (average) effect of treatment was
in patients who would have adhered to protocol however
they were randomised [7]. These questions are different,
and observing different results should not shake our con-
fidence in either. The CACE analysis was a secondary
analysis, not a sensitivity analysis.
It is common for authors to compare the results
of intention-to-treat with per-protocol analysis; see for
example [8,9]. While it is hard to pin down the pre-
cise question of per-protocol analysis [10], this is clearly
different to the question intention-to-treat addresses. Per-
protocol analysis should not therefore be considered as
a sensitivity analysis for intention-to-treat but as a sec-
ondary analysis, if at all.
Is it possible for the proposed sensitivity analysis to arrive
at a different conclusion to the primary analysis?
This question aims to check whether an alternative anal-
ysis can be considered a sensitivity analysis or if it is a
foregone conclusion. Performing two different analyses
Does the proposed sensitivity analysis address the
same question as the primary analysis? No Secondary analysis
Yes
Is it possible for the proposed sensitivity analysis
to arrive at a different conclusion to the primary
analysis?
No Nonsensitivity analysis
Yes Unsure
Can dataset/s be con-
structed for which the prin-
cipal and sensitivity analy-
ses disagree
If the proposed sensitivity analysis led to a dif-
ferent conclusion to the primary analysis, would
there be any genuine uncertainty as to which
would be preferred?
No Futile analysis
Yes
Include sensitivity analysis in statistical analysis
plan
Figure 1 Questions for a sensitivity analysis. Schematic for deciding whether to proceed with the proposed sensitivity analysis.
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does not mean they can lead to different results. If they
cannot, the analysis is misguided and can tell us nothing
about the sensitivity of our conclusions.
If the answer to this question is unclear at the stage of
writing the statistical analysis plan, a helpful exercise is
to attempt to construct one or more datasets in which
the primary and sensitivity analysis disagree. If sensitivity
analyses are motivated by concerns about certain features
of the data, this should not be difficult.
Example
Consider the proposal for handling missing data in Table
two of Thabane et al [5]. The suggestion is to ‘analyse only
complete cases’ and then ‘impute the missing data . . . and
redo the analysis’. This will not necessarily assess how
robust the results are to the missing data, as demonstrated
by the following example.
In a protocol for an ongoing study, Zheng et al. describe
a randomised trial aiming to assess the effect of Baduanjin
exercise on physical and mental health in 222 college
students [11]. The primary analysis will compare the
mean lumbar muscle strength using a t-test. It is antic-
ipated that outcomes will be missing for some partici-
pants. (The following is our illustration, and not described
by the authors.) Assume that the primary analysis is
in complete cases only, but the investigators wish to
investigate how sensitive results are to dropping partic-
ipants with missing data. They decide to use multiple
imputation, where the model for imputation assumes
lumbar muscle strength is normally distributed with dif-
ferent means but equal variances in the two treatment
groups.
The imputation model described makes identical
assumptions to the t-test and, with a sufficient number
of imputations, the multiple imputation analysis will give
near identical results. Simply imputing data does not nec-
essarily make different assumptions. The fact that the
results of two analyses are almost identical should not be
reassuring: this is equivalent to being reassured that run-
ning one analysis twice gives the same results. Running
two analyses which make identical assumptions gives us
false confidence in the robustness of results. Note that this
analysis may have value as a check that multiple impu-
tation is working correctly, but only as a springboard to
other imputation approaches.
Is there a genuine degree of uncertainty as to which
analysis will be believed?
Assume the proposed sensitivity analysis addresses the
same question as the primary analysis and can lead to dif-
ferent conclusions. It should then be considered whether
either analysis is obviously and always to be preferred.
If it is clear that one analysis would always be believed
over the other, the former should be the primary analysis
and the latter should not be done. Sensitivity analy-
sis is not an opportunity to perform an unreasonable
analysis.
A sensitivity analysis should be derived from assump-
tions that seem plausible. With respect to the trial design,
particularly strong, questionable or untestable assump-
tionsmade by the primary analysis should, where possible,
be addressed by one or more alternative analyses that
make different assumptions. Given the trial design and
assumptions, the sensitivity analysis should be asymptoti-
cally unbiased for estimation of the treatment effect, and
control the rate of type I errors, and thus coverage. The
sensitivity analysis may be less powerful than the primary
analysis.
Example
Returning to the missing data example above, if Zheng
et al. were to use single (as opposed to multiple) impu-
tation as a sensitivity analysis, as suggested in [5], this
could well lead to different conclusions, despite our crit-
icism above that the model for imputation is identical
to the model for the primary analysis. Single imputa-
tion fails to allow for the uncertainty induced by missing
data, and does not in general lead to valid inferences
[12]. The estimated standard error of the treatment effect
will be too small, implying inflation of type I error rates
and under-coverage of confidence intervals. The analy-
sis should thus not undermine the primary analysis of
covariance.
Similarly, performing ‘one analysis that accounts for
clustering and one that ignores it’, as proposed in [5],
may be unwise. In general an analysis that accounts for
clustering is used because clustering arises through the
design [13]. If a cluster-randomised trial were primar-
ily analysed allowing for the clustering, but a subsequent
analysis ignoring the clustering led to different conclu-
sions, there would be no degree of uncertainty as to which
we believe. However, the best approach to account for
clustering may be unclear. Hu et al. consider approaches
to analysing a study with a longitudinal binary outcome
[14], comparing random effects approaches with gener-
alised estimating equations. This is reasonable because
there tends to be some uncertainty as to which method is
preferred.
Caveat: practical constraints
We note that there may be settings where exceptions
to the third question are made for unavoidable rea-
sons. For example, constraints on time, reliance on a
methodology which is not well understood at the stage
of writing, and a lack of software with the ability to run
the analysis may make the ‘preferred analysis’ imprac-
tical for certain cases. This may happen in exceptional
cases.
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Example
The Paramedic trial is designed to assess whether survival
of cardiac arrest patients can be improved by equipping
ambulances with a mechanical chest compression device,
compared to manual chest compressions by the crew [15].
Ambulances are randomised in a 1:2 ratio. Ambulances
may move between different sites, and the crewmaymove
between ambulances and sites, meaning the data involves
cross-classified clustering. The principal analysis for this
trial accounts for ambulance, but not for crew mem-
bers, or the site the ambulance left from or returned to.
Although an analysis which fully accounts for all three
types of clustering may be preferred in theory, fitting
such a model may be difficult, and might require the
development of new methods and software.
We expect this issue to be rare. It arises because one
analysis is preferred in theory but not in practice, and so
the answer the question 3 can in fact be regarded as no.
Examples
Further examples of proposed sensitivity analyses which
our questions regard as reasonable are given below.
Missing data assumptions
Consider again the trial described by Zheng et al [11].
Recall that the continuous outcome is anticipated to be
missing for some participants. Suppose the primary anal-
ysis assumes data are missing at random and multiply
imputes lumbar muscle strength separately for the two
treatment groups, using an imputation model that also
conditions on secondary (auxiliary) outcomes such as
physical fitness, stress and quality of life. This primary
analysis is valid under a missing at random assumption,
and may give different results to analysis of the com-
plete cases. However the assumption that missing values
are missing at random is untestable. What if the data are
trulymissing not at random? It is considered plausible that
lumbar muscle strength is less likely to be observed in
individuals with lower values, and so missing values might
on average be one unit lower than the observed outcomes
of otherwise comparable individuals. Our sensitivity anal-
ysis might then be to subtract one from every imputed
value and re-analyse the imputed data. Further sensi-
tivity analyses could assume that this mechanism only
occurred within one treatment group, that it was stronger
than subtract one, or that it was in the opposite direction
(add one) [16].
The sensitivity analyses are reasonable because they:
1) address the same question as the primary analysis,
under different assumptions; 2) may or may not lead to
different conclusions; and 3) involve different assump-
tions which may be plausible, although some may be less
so: there is genuine uncertainty about the most plausible
assumption [16].
Definitions of outcome
In a randomised trial in neutropenic patients, de Pauw
et al. considered the effect of antifungal therapy on out-
come [17]. The primary outcome was defined by a five-
part composite endpoint, one part being ‘fever resolution’.
Because fever resolution was hard to define, sensitivity
analyses included using alternative definitions and feeding
these into the five-part composite endpoint.
The Copers trial [18] is designed to evaluate a self-
management course for patients with chronic muscu-
loskeletal pain. The primary outcome is the mean of of
three questions about Q1) the amount of pain-related
disability the participant is currently experiencing, and
whether the participant’s ability to Q2) work, and Q3)
interact socially, has changed. Each is scored out of 10
with a high score intended to identify a negative out-
come for all three questions. However, there is concern
that for Q2 and Q3 some participants may be confused
about whether a high or low score indicates a negative
outcome. A planned sensitivity analysis is thus to rede-
fine participants’ answers so that anyone with a score
of two or lower for Q1, but eight or higher for Q2 or
Q3 has their scoring reversed for Q2 and/or Q3. The
primary analysis is then repeated with this definition of
outcome.
Ideally, outcome variables would be unambiguously
defined, but this is not always the case. For both of the
above examples we regard the answer to our three ques-
tions as ‘yes’. The same question is being addressed, but
assumptions about the definition of outcome are different,
and it is not certain that one definition is correct.
Summary
Sensitivity analyses should be carefully chosen and pre-
defined as far as possible, where the proposed analyses
involve a range of plausible and contrasting assumptions.
Some analyses should rightly be given more emphasis
than others, and the primary analysis should be the one
that seems to carry the most weight prior to seeing the
data. Our three questions help to identify whether an
alternative analysis is reasonable as a sensitivity analysis.
It is the need to prespecify analyses that makes these
questions particularly useful in the context of randomised
trials. However, they are also helpful with observational
studies and when applied post-hoc.
Through discussions with trial statisticians we believe
sensitivity analyses are used widely, but often infor-
mally, and results are largely unreported. If the screening
questions outlined above are considered at the stage of
writing the statistical analysis plan, sensitivity analyses
will be relevant to the clinical question, and the num-
ber to perform and report will be reduced. We hope
that in future they will be sensibly chosen and more
widely reported.
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